Hybrid immunity and SARS-CoV-2 antibodies: results of the HEROES-RECOVER prospective cohort study
James K Romine,Huashi Li,Melissa M Coughlin,Jefferson M Jones,Amadea Britton,Harmony L Tyner,Sammantha B Fuller,Robin Bloodworth,Laura J Edwards,Jini N Etoule,Tyler C Morrill,Gabriella Newes-Adeyi,Lauren E W Olsho,Manjusha Gaglani,Ashley Fowlkes,James Hollister,Edward J Bedrick,Jennifer L Uhrlaub,Shawn Beitel,Ryan S Sprissler,Zoe Lyski,Cynthia J Porter,Patrick Rivers,Karen Lutrick,Alberto J Caban-Martinez,Sarang K Yoon,Andrew L Phillips,Allison L Naleway,Jefferey L Burgess,Katherine D Ellingson
DOI: https://doi.org/10.1093/cid/ciae130
IF: 20.999
2024-03-12
Clinical Infectious Diseases
Abstract:There are limited data on whether hybrid immunity differs by count and order of immunity-conferring events (SARS-CoV-2 infection or COVID-19 vaccination). From a cohort of health care personnel, first responders, and other frontline workers in six US states, we examined heterogeneity of the effect of hybrid immunity on SARS-CoV-2 antibody levels. Exposures included event-count (sum of infections and vaccine doses) and event-order, categorized into seven permutations of vaccination and/or infection. Outcome was level of serum binding antibodies against receptor binding domain (RBD) of the ancestral SARS-CoV-2 spike protein (total RBD-binding Ig), measured by enzyme-linked immunosorbent assay. Mean antibody levels were examined up to 365 days after each of the 1 st -7 th events. Analysis included 5,793 participants measured from August 7, 2020 to April 15, 2023. Hybrid immunity from infection before one or two vaccine doses elicited modestly superior antibody responses after the 2 nd and 3 rd events (compared to infections or vaccine-doses alone). This superiority was not evident after the 4 th and 5 th events (additional doses). Among adults infected before vaccination, adjusted geometric mean ratios (95% CI) of anti-RBD early response (versus vaccinated-only) were 1.23 (1.14-1.33), 1.09 (1.03-1.14), 0.87 (0.81-0.94), and 0.99 (0.85-1.15) after the 2 nd -5 th events, respectively. Post-vaccination infections elicited superior responses: adjusted geometric mean ratios (95% CI) of anti-RBD early response (versus vaccinated-only) were: 0.93 (0.75-1.17), 1.11 (1.06-1.16), 1.17 (1.11-1.24), and 1.20 (1.07-1.34) after the 2 nd -5 th events, respectively. Findings reflecting heterogeneity in antibody levels by permutations of infection and vaccination history could inform COVID-19 vaccination policy.
immunology,infectious diseases,microbiology